Jasper Therapeutics, Inc. is under legal scrutiny following a class action lawsuit filed by DJS Law Group. The case alleges the company violated key provisions of the Securities Exchange Act, potentially impacting the rights and investments of shareholders.

William Blair has lowered its third-quarter 2025 earnings forecast for Jasper Therapeutics to a loss of $0.75 per share, according to an analyst note issued on August 14. The deeper-than-expected projection, reported by Defenseworld.net, signals mounting challenges for the California-based biotech firm.